Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 6/20 | 0.35 |
| ▸ | BUB1 | O43683 | 2/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 2/20 | 0.34 |
| ▸ | CDK4 | P11802 | 4/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30371863 | 0.91 | BRD4 (0.39) | BRD4EGFRITKBUB1SLC16A3 | |
| SCHEMBL25447126 | 0.91 | BRD4 (0.39) | BRD4EGFRITKBUB1SLC16A3 | |
| SCHEMBL25447130 | 0.90 | BRD4 (0.38) | BRD4EGFRITKBUB1SLC16A3 | |
| SCHEMBL24105052 | 0.87 | AURKA (0.39) | AURKACDK2CDK4AURKBCDK1 | |
| SCHEMBL30167782 | 0.87 | AURKA (0.39) | AURKACDK2CDK4AURKBCDK1 | |
| SCHEMBL25176456 | 0.87 | AURKA (0.37) | AURKACDK2CDK4AURKBCDK1 | |
| SCHEMBL22124312 | 0.85 | BRD4 (0.41) | BRD4EGFRITKBUB1TTK | |
| SCHEMBL30171675 | 0.85 | BRD4 (0.41) | BRD4EGFRITKBUB1JAK2 | |
| SCHEMBL30385261 | 0.84 | BRD4 (0.39) | BRD4EGFRITKBUB1AXL | |
| SCHEMBL30172091 | 0.83 | ITK (0.39) | BRD4EGFRITKBUB1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | BRD4 805/4885EGFR 1449/4885ITK 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.